Visual acuity equal to or above 0.5 in the study eye
Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye
Receiving IOP-lowering glaucoma treatment
Nerve fiber layer defects identified by OCT
You may not be if
Diabetes or renal impairment
Medical history of significant eye disease (including ocular trauma) other than glaucoma
Ocular inflammation/infection within three months from inclusion
Intraocular surgery 3 months before inclusion
Smoker at the time of inclusion
Pregnant or breast-feeding
Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence
Subjects allergic to drug ingredients administered during the trial
Subjects with untreated severe systemic disease or malignancies
